. Et-sa-pédagogie, A Laure et Bérénice, qui m'ont accompagnée durant ce semestre à tour de rôle

M. Cole, C. Jones, and I. Todd, A New Anti-oestrogenic Agent in Late Breast Cancer

H. Ward, Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels, BMJ, vol.1, issue.5844, pp.13-17, 1973.
DOI : 10.1136/bmj.1.5844.13

K. Pritchard, Adjuvant therapy of the very young woman. The Breast, pp.16-136, 2007.

V. Bramwell and K. Pritchard, Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: is it standard practice or still a subject for study?, European Journal of Cancer, vol.35, issue.12, pp.1625-1632, 1999.
DOI : 10.1016/S0959-8049(99)00204-X

R. Day, P. Ganz, J. Costantino, W. Cronin, D. Wickerham et al., Health-Related Quality of Life and Tamoxifen in Breast Cancer Prevention: A Report From the National Surgical Adjuvant Breast and Bowel Project P-1 Study, Journal of Clinical Oncology, vol.17, issue.9, pp.2659-69, 1999.
DOI : 10.1200/JCO.1999.17.9.2659

A. Sacks, N. Baum, and M. , The Royal Marsden Hospital pilot tamoxifen chemoprevention trial, Breast Cancer Res Treat, vol.31, issue.1, pp.73-82, 1994.

T. Powles, R. Eeles, and S. Ashley, Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial, The Lancet, vol.352, issue.9122, pp.98-101, 1998.
DOI : 10.1016/S0140-6736(98)85012-5

J. Cuzick and M. Baum, TAMOXIFEN AND CONTRALATERAL BREAST CANCER, The Lancet, vol.326, issue.8449, p.282, 1985.
DOI : 10.1016/S0140-6736(85)90338-1

I. Gerhard and B. Runnebaum, Comparison between tamoxifen and clomiphene therapy in women with anovulation, Archives of Gynecology, vol.6, issue.4, pp.297-88, 1979.
DOI : 10.1111/j.1471-0528.1973.tb11230.x

G. Groom and K. Griffiths, EFFECT OF THE ANTI-OESTROGEN TAMOXIFEN ON PLASMA LEVELS OF LUTEINIZING HORMONE, FOLLICLE-STIMULATING HORMONE, PROLACTIN, OESTRADIOL AND PROGESTERONE IN NORMAL PRE-MENOPAUSAL WOMEN, Journal of Endocrinology, vol.70, issue.3, pp.421-429, 1976.
DOI : 10.1677/joe.0.0700421

J. Heuson, Current overview of EORTC clinical trials with tamoxifen, Cancer Treat Report, vol.60, pp.1463-1469, 1976.

V. Ruiz-velasco, R. Rosas-arceo, J. Matute, and M. , Clinical inducers of ovulation : comparative results, Int J Fertil, vol.24, pp.61-65, 1979.

B. Senior, M. Cawood, R. Oakley, J. Mckiddie, and D. Siddle, A COMPARISON OF THE EFFECTS OF CLOMIPHENE AND TAMOXIFEN TREATMENT ON THE CONCENTRATIONS OF OESTRADIOL AND PROGESTERONE IN THE PERIPHERAL PLASMA OF INFERTILE WOMEN, Clinical Endocrinology, vol.80, issue.5, pp.381-390, 1978.
DOI : 10.1111/j.1471-0528.1973.tb11230.x

M. Shaaban and F. Morad, Treatment of Fibrocystic Mastopathy by an Antiestrogen, Tamoxifen, International Journal of Gynecology & Obstetrics, vol.89, issue.5, pp.348-50, 1980.
DOI : 10.1136/bmj.1.5844.13

V. Jordan, N. Fritz, D. Langan-fahey, M. Thompson, and D. Tormey, Alteration of Endocrine Parameters in Premenopausal Women With Breast Cancer During Long-Term Adjuvant Therapy With Tamoxifen as the Single Agent, JNCI Journal of the National Cancer Institute, vol.83, issue.20, pp.1488-91, 1991.
DOI : 10.1093/jnci/83.20.1488

P. Ravdin, N. Fritz, D. Tormey, and V. Jordan, Endocrine status of premenopausal node positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen

A. Sasco, R. Ah-song, S. Saez, and F. Kutten, Effets secondaires médicaux d'une intervention de chimioprévention : l'exemple du tamoxifène, Bull Cancer, vol.82, issue.3, pp.186-206, 1995.

B. Sherman, F. Chapler, K. Crickard, and D. Wykoff, Endocrine Consequences of Continuous Antiestrogen Therapy with Tamoxifen in Premenopausal Women, Journal of Clinical Investigation, vol.64, issue.2, pp.398-404, 1979.
DOI : 10.1172/JCI109475

V. Jordan, N. Fritz, and D. Tormey, Endocrine effets of adjuvant chemotherapy and longterm tamoxifen administration on node-positive patients with breast cancer, Cancer Res, vol.47, pp.624-654, 1987.

R. Barbieri, A. Ferracci, J. Droesch, and B. Rochelson, Ovarian torsion in a premenopausal woman treated with tamoxifen for breast cancer**Supported in part by grant HD24563 from the National Institutes of Health, Bethesda, Maryland., Fertility and Sterility, vol.59, issue.2, pp.459-60, 1993.
DOI : 10.1016/S0015-0282(16)55688-X

I. Cohen and A. Figer, Ovarian Overstimulation and Cystic Formation in Premenopausal Tamoxifen Exposure: Comparison between Tamoxifen-Treated and Nontreated Breast Cancer Patients, Gynecologic Oncology, vol.72, issue.2, pp.202-209, 1999.
DOI : 10.1006/gyno.1998.5201

I. Cohen and R. Tepper, Successful co-treatment with LH-RH-agonist for ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure, Breast Cancer Res Treat, vol.55, issue.2, pp.119-141, 1999.

D. Hochner-celnikier, E. Anteby, and S. Yagel, Ovarian cysts in tamoxifen-treated premenopausal women with breast cancer???A management dilemma, American Journal of Obstetrics and Gynecology, vol.172, issue.4, pp.1323-1327, 1995.
DOI : 10.1016/0002-9378(95)91511-7

S. Ismail, Gynaecological effects of tamoxifen, Journal of Clinical Pathology, vol.52, issue.2, pp.83-91, 1999.
DOI : 10.1136/jcp.52.2.83

W. Mccluggage and P. Weir, Paraovarian cystic endosalpingiosis in association with tamoxifen therapy, Journal of Clinical Pathology, vol.53, issue.2, pp.161-163, 2000.
DOI : 10.1136/jcp.53.2.161

M. Mourits, D. Vries, E. Willemse, P. Ten-hoor, K. Hollema et al., Ovarian cysts in women receiving tamoxifen for breast cancer, British Journal of Cancer, vol.132, issue.11-12, pp.11-121761, 1999.
DOI : 10.1093/oxfordjournals.aje.a116427

URL : http://www.nature.com/bjc/journal/v79/n11/pdf/6690280a.pdf

K. Nasu, T. Miyazaki, Y. Kiyonaga, F. Kawasaki, and I. Miyakawa, Torsion of a Functional Ovarian Cyst in a Premenopausal Patient Receiving Tamoxifen, Gynecologic and Obstetric Investigation, vol.48, issue.3, pp.200-202, 1999.
DOI : 10.1159/000010174

D. Tormey, R. Simon, R. Lippman, J. Bull, and C. Myers, Evaluation of tamoxifen dose in advanced breast cancer : a progress report, Cancer Treat Rep, vol.60, issue.10, pp.1451-1460, 1976.

W. Cheng and H. Lin, Comparison of endometrial changes among symptomatic tamoxifen-treated and non treated premenopausal and postmenopausal breast cancer patients

A. Sasco, Tamoxifen and menopausal status: risks and benefits, The Lancet, vol.347, issue.9003, p.761, 1996.
DOI : 10.1016/S0140-6736(96)90111-7

. Lasset, C. Bonadonna, F. Chauvin, H. Mignotte, and A. Bremond, Risk of endometrial cancer in premenopausal women on tamoxifen, The Lancet, vol.352, issue.9138, p.1476, 1998.
DOI : 10.1016/S0140-6736(05)61308-6

A. Lesur, B. Cutuli, M. Teissier, and E. Luporsi, Place des inhibiteurs de l???aromatase dans le cancer du sein de la femme m??nopaus??e, en situation adjuvante: les acquis et les incertitudes en 2005, Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.35, issue.4, pp.327-367, 2006.
DOI : 10.1016/S0368-2315(06)76405-5

J. Bines, D. Oleske, and M. Cobleigh, Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer., Journal of Clinical Oncology, vol.14, issue.5, pp.1718-1747, 1996.
DOI : 10.1200/JCO.1996.14.5.1718

M. Berliere, F. Duhoux, F. Dalenc, J. Baurain, L. Dellevigne et al., Tamoxifen and Ovarian Function, PLoS ONE, vol.8, issue.2, p.66616, 2013.
DOI : 10.1371/journal.pone.0066616.t003

URL : https://doi.org/10.1371/journal.pone.0066616

M. Pritchard and K. , National Cancer Institute of Canada Clinical Trials Group. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study

J. Walshe, N. Denduluri, and S. Swain, Amenorrhea in Premenopausal Women After Adjuvant Chemotherapy for Breast Cancer, Journal of Clinical Oncology, vol.24, issue.36, pp.5769-79, 2006.
DOI : 10.1200/JCO.2006.07.2793

S. Aebi, S. Gelber, M. Castiglione-gertsch, R. Gelber, J. Collins et al., Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?, The Lancet, vol.355, issue.9218, pp.1869-74, 2000.
DOI : 10.1016/S0140-6736(00)02292-3

H. Burstein, E. Mayer, A. Patridge, O. Kane, H. Litsas et al., Inadvertent Use of Aromatase Inhibitors in Patients with Breast Cancer with Residual Ovarian Function: Cases and Lessons, Clinical Breast Cancer, vol.7, issue.2, pp.158-61, 2006.
DOI : 10.3816/CBC.2006.n.026

J. Taffe, C. Garamszegi, E. Dudley, and L. Dennerstein, Determinants of self rated menopause status, Maturitas, vol.27, issue.3, pp.223-232, 1997.
DOI : 10.1016/S0378-5122(97)00043-1

R. Bell, M. Lijovic, P. Fradkin, and S. Davis, A pragmatic approach to the classification of menopausal status for community-based research, Menopause, vol.15, issue.5, pp.978-83, 2008.
DOI : 10.1097/gme.0b013e318162c487

A. Phipps, L. Ichikawa, E. Bowles, P. Carney, K. Kerlikowske et al., Defining menopausal status in epidemiologic studies: A comparison of multiple approaches and their effects on breast cancer rates, Maturitas, vol.67, issue.1, pp.60-66, 2010.
DOI : 10.1016/j.maturitas.2010.04.015

C. Jolles, D. Smotkin, K. Ford, and K. Jones, Cystic ovarian necrosis complicating tamoxifen therapy for breast cancer in a premenopausal woman. A case report, J Reprod Med, vol.35, issue.3, pp.299-300, 1990.

F. Boccardo, A. Rubagotti, D. Amoroso, P. Sismondi, F. Genta et al., Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (breast cancer adjuvant chemo-hormone therapy cooperative group) trial, European Journal of Cancer, vol.28, issue.2-3, pp.2-3673, 1992.
DOI : 10.1016/S0959-8049(05)80123-6

URL : https://hal.archives-ouvertes.fr/hal-00616696

I. Cohen, Y. Beyth, R. Tepper, J. Shapira, Y. Zalel et al., Ovarian Tumors in Postmenopausal Breast Cancer Patients Treated with Tamoxifen, Gynecologic Oncology, vol.60, issue.1
DOI : 10.1006/gyno.1996.0011

A. Shushan, T. Peretz, and S. Mor-yosef, Therapeutic approach to ovarian cysts in tamoxifen-treated women with breast cancer, International Journal of Gynecology & Obstetrics, vol.125, issue.3, pp.249-53, 1996.
DOI : 10.1210/endo-125-3-1739

A. Shushan, T. Peretz, B. Uziely, A. Lewin, and S. Mor-yosef, Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer, American Journal of Obstetrics and Gynecology, vol.174, issue.1, pp.141-145, 1996.
DOI : 10.1016/S0002-9378(96)70386-1

B. Fisher, J. P. Costantino, D. L. Wickerham, C. K. Redmond, M. Kavanah et al., Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, JNCI: Journal of the National Cancer Institute, vol.97, issue.22, pp.1652-62, 2005.
DOI : 10.1016/j.ejca.2004.10.020

W. Lorizio, A. Wu, and M. Beattie, Clinical and biomarker predictors of side effects from tamoxifen, Breast Cancer Research and Treatment, vol.14, issue.2, pp.1107-1125, 2012.
DOI : 10.1097/01.gme.0000233496.13088.24

N. Jager, R. Koornstra, and A. Vincent, Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites, BMC Cancer, vol.70, issue.4, p.612, 2013.
DOI : 10.1016/j.maturitas.2011.09.011

L. Madlensky, L. Natarajan, S. Tchu, M. Pu, J. Mortimer et al., Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes, Clinical Pharmacology & Therapeutics, vol.169, issue.5, pp.718-743, 2011.
DOI : 10.1093/aje/kwp077

URL : http://europepmc.org/articles/pmc3081375?pdf=render

J. Cuzick and M. Dowsett, CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients, J Natl Cancer Inst, vol.104, issue.6, pp.452-60, 2012.

M. Biasi, B. Thürlimann, and M. Lyng, CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer : the breast international groupe 1-98 trial, J Natl Cancer Inst, vol.104, issue.6, pp.441-51, 2012.

H. Brauch, W. Schroth, M. Goetz, T. Mürdter, S. Winter et al., Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters, Journal of Clinical Oncology, vol.31, issue.2, pp.176-80, 2012.
DOI : 10.1200/JCO.2012.44.6625

J. Mortimer, S. Flatt, B. Parker, E. Gold, L. Wasserman et al., Tamoxifen, hot flashes and recurrence in breast cancer, Breast Cancer Research and Treatment, vol.22, issue.3, pp.421-427, 2008.
DOI : 10.1093/jnci/djg108

J. Cuzick, I. Sestak, D. Cella, L. Fallowfield, and A. Trialists, Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial, The Lancet Oncology, vol.9, issue.12, pp.1143-1151, 2008.
DOI : 10.1016/S1470-2045(08)70259-6

R. Hernandez, H. Sørensen, L. Pedersen, J. Jacobsen, and T. Lash, Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism, Cancer, vol.18, issue.19, pp.4442-4451, 2009.
DOI : 10.1002/cncr.24508

T. Saphner, D. Tormey, and R. Gray, Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer., Journal of Clinical Oncology, vol.9, issue.2, pp.286-94, 1991.
DOI : 10.1200/JCO.1991.9.2.286

P. Goodwin, M. Ennis, K. Pritchard, D. Mccready, K. J. Sidlofsky et al., Adjuvant Treatment and Onset of Menopause Predict Weight Gain After Breast Cancer Diagnosis, Journal of Clinical Oncology, vol.17, issue.1, pp.120-129, 1999.
DOI : 10.1200/JCO.1999.17.1.120